There are currently 328 ongoing clinical trials involving Hepatitis C
Of the 328 trials,129 trials are in Phase IV
Furthermore, 94 trials are in Phase II
The global pharmaceutical industry is steadily developing new drugs for Hepatitis C, Infectious Disease. Europe, Asia-Pacific, and North America are some of the prominent regions engaged in Hepatitis C-related drug trials.
Hepatitis C related clinical trial sponsors
AbbVie Inc, The Kirby Institute, Ain Shams University and University of Pittsburgh are some of the notable clinical trial sponsors involved in Hepatitis C. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Hepatitis C
Grazoprevir (MK-5172) and Elbasvir (MK-8742) (Zepatier), Glecaprevir and pibrentasvir (Maviret, Mavyret), Sofosbuvir and Velpatasivir (Epclusa) are among the key marketed drugs involving Hepatitis C.
Grazoprevir (MK-5172) and Elbasvir (MK-8742) (Zepatier) is a fixed dose combination drug acts as an antiviral agent. It functions via Hepacivirin (NS3/4A Protease or NS3 Serine Proteinase or EC 3.4.21.98) Inhibitor; Nonstructural Protein 5A (NS5A) Inhibitormechanism of action. It is formulated as film coated tablets and tablets for oral route of administration. Zepatier is indicated for the treatment of chronic hepatitis C (CHC) genotypes 1, 3, or 4 infection in adults as follows : Without ribavirin: in genotype (GT) 1 or 4 treatment-naïve (TN) and peginterferon alfa + ribavirin (PR) treatment-experienced (TE) relapsers (12 weeks), in GT1 protease inhibitor (PI)/PR-TE relapsers (12 weeks), in GT1b TN, non-cirrhotic patients (8 weeks), in GT1b PR- or PI/PR-TE on-treatment virologic failures (12 weeks), With Ribavirin : in GT1a PR- or PI/PR-TE on-treatment virologic failures (16 weeks), in GT4 PR-TE on-treatment virologic failures (16 weeks), With sofosbuvir: in GT3 TN patients (12 weeks). Zepatier is indicated for use with ribavirin in certain patient populations. Grazoprevir (MK-5172) and Elbasvir (MK-8742) was first approved in 2016 and is marketed globally including the US, the UK, Australia, France, and Germany by Merck & Co Inc and its subsidiaries.
Glecaprevir and pibrentasvir (Maviret, Mavyret) is a fixed dose combination drug, acts as antiviral agent. It functions via Hepacivirin (NS3/4A Protease or NS3 Serine Proteinase or EC 3.4.21.98) Inhibitor; Nonstructural Protein 5A (NS5A) Inhibitor mechanism of action. It is formulated as film coated tablets, coated granules and pellets for oral route of administration. Maviret is indicated for the treatment of hepatitis C virus infection in adults. Mavyret is indicated to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also approved for adult patients with HCV genotype 1 infection who have been previously treated with a regimen either containing an NS5A inhibitor or an NS3/4A protease inhibitor but not both, and also indicated for treatment of all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17 and treatment of chronic hepatitis C (HCV) with naive, compensated cirrhotic, genotype (GT)1, 2, 4, 5, and 6 infection patients. Maviret is indicated for the improvement of viremia in pediatric patients 3 years or older, with chronic hepatitis C or compensated cirrhosis type C. Mavyret is indicated for the treatment of adults and children aged 3 years and older or weighing at least 99 pounds who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection and compensated cirrhosis and have not been previously treated for HCV (treatment-naive). Glecaprevir and pibrentasvir was first approved in 2017 and is marketed globally including the US, the UK, Australia, France, and Germany by AbbVie Inc and its subsidiaries.
China
Switzerland
United States of America
United States of America
United States of America
United States of America
France
Switzerland
United Kingdom
United States of America
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward